FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313305164> ?p ?o ?g. }

• W4313305164 abstract "Article Figures and data Abstract Editor's evaluation Introduction Results Discussion Materials and methods Data availability References Decision letter Author response Article and author information Metrics Abstract Collapsin response mediator proteins (CRMPs) are key for brain development and function. Here, we link CRMP1 to a neurodevelopmental disorder. We report heterozygous de novo variants in the CRMP1 gene in three unrelated individuals with muscular hypotonia, intellectual disability, and/or autism spectrum disorder. Based on in silico analysis these variants are predicted to affect the CRMP1 structure. We further analyzed the effect of the variants on the protein structure/levels and cellular processes. We showed that the human CRMP1 variants impact the oligomerization of CRMP1 proteins. Moreover, overexpression of the CRMP1 variants affect neurite outgrowth of murine cortical neurons. While altered CRMP1 levels have been reported in psychiatric diseases, genetic variants in CRMP1 gene have never been linked to human disease. We report for the first-time variants in the CRMP1 gene and emphasize its key role in brain development and function by linking directly to a human neurodevelopmental disease. Editor's evaluation The authors report the first human disease-related variants in CRMP1 leading to a neurodevelopmental syndrome. After a successful first review, the authors have addressed the reviewer comments fully and have carefully assessed and fulfilled the criteria for essential revisions with the inclusion of new data. The results will be of importance to cell biologists and clinicians. https://doi.org/10.7554/eLife.80793.sa0 Decision letter Reviews on Sciety eLife's review process Introduction Neurodevelopment is a fine-tuned process orchestrated by distinct expression and function of several genes and any disturbances in this timely controlled process culminate in neurodevelopmental disorder (Rice and Barone, 2000; Gilbert et al., 2005). Collapsin response mediator proteins (CRMPs) are cytosolic phosphoproteins that are highly and differentially expressed in the nervous system (Wang and Strittmatter, 1996; Bretin et al., 2005). The five CRMP subtypes (CRMP1–5) form homo- or hetero-tetramers in various combinations and thereby enable distinct functions key for neurodevelopment (Wang and Strittmatter, 1997). Targeted neurodevelopmental processes include cell migration, axonal outgrowth, dendritic branching, apoptosis mediated through extracellular signaling molecules (Sema3A, reelin, neurotrophins) (Yamashita et al., 2006; Su et al., 2007; Charrier et al., 2006; Yamashita et al., 2007; Makihara et al., 2016). CRMP function is regulated in a spatiotemporal manner through protein phosphorylation mediated by various kinases such as Cdk5, Rho/ROCK, and GSK3 (Yoshimura et al., 2005; Uchida et al., 2005). Given their key function in developmental processes, disturbances in CRMP function can result in neurodevelopmental diseases. In this line, monoallelic CRMP5 variants can cause Ritscher–Schinzel syndrome 4 (MIM#619435), a neurodevelopmental disease with craniofacial features, cerebral and cardiovascular malformations, and cognitive dysfunction (Jeanne et al., 2021). CRMP4 variants have been associated with amyotrophic lateral sclerosis in the French population (Blasco et al., 2013). Here, we link for the first-time CRMP1 variants in three unrelated pedigrees to neurodevelopmental disorder in humans with muscular hypotonia, autism spectrum disorder (ASD), and/or intellectual disability. In humans, maternal CRMP1 autoantibodies have been associated with autism in their children, and increased CRMP1 mRNA levels were identified in individuals with schizophrenia, attention-deficit hyperactivity disorder, and ASD (Braunschweig et al., 2013; Bader et al., 2012). Knockout of Crmp1 in mice results in schizophrenia-associated behavior, impaired learning and memory, and prepulse inhibition (Yamashita et al., 2013). At the cellular level, abnormal neurite outgrowth, dendritic development and orientation, and spine maturation of cortical and/or hippocampal neurons have been shown (Su et al., 2007; Yamashita et al., 2007; Makihara et al., 2016). Loss of Crmp1 affects long-term potentiation maintenance (Su et al., 2007). In addition, its loss during cerebellar development leads to reduced granule cell proliferation, apoptosis, and migration in the cerebellum of Crmp1−/− mice (Charrier et al., 2006). Although evidence on altered levels of CRMP1 in neuropsychiatric diseases exists, the variants in the CRMP1 gene have not been linked to a human disease. Results Phenotype and genotype of index patients Proband 1 (P1) was born as the second child of non-consanguineous healthy parents of Caucasian descent after an uneventful pregnancy (Figure 1A, Table 1). At delivery a singular umbilical artery was noted. The global development was delayed from infancy on: with sitting at 18 months, standing with support at 14 months, walking at 26 months, first words at 24 months. She had slurred speech. Standardized cognitive tests performed at 5 and 10 years revealed a moderate intellectual disability with an intelligence quotient (IQ) of 55 at last assessment using the Kaufman Assessment Battery for Children (K-ABC). Behavioral problems included a lack of distance to men and a sexualized behavior. At last assessment at 16 years-of-age, the girl had generalized muscular hypotonia with normal reflexes, but fine motor problems with a broad-based gait but no ataxia. When climbing stairs, she showed clear instability. The results of cranial magnetic resonance imaging (MRI) at 1.5 and 4 years as well as that of further work-up (including metabolic tests, electroencephalogram [EEG], ophthalmological assessment, electrocardiogram, echocardiogram, and abdominal sonography) were normal. Since preliminary genetic tests including chromosome analysis and array-CGH were normal in the index patient (P1), we performed whole-exome sequencing (WES) to identify the underlying genetic cause. WES followed by bioinformatic analysis and confirmation with Sanger sequencing revealed the heterozygous de novo variant in the CRMP1 gene c.1766C>T (NM_001014809.2; Chr4 (GRCh37):g.5830253G>A) in the affected child P1 (Figure 1B; Figure 1—figure supplement 1). At the protein level, this variant leads to an amino acid change at position 589 from proline to leucine: P589L in long isoform, CRMP1A (NP_001014809.1), and P475L in short form, CRMP1B (NP_001304.1) (Figure 1B). The identified variant was not found in 1000Genomes, dbSNP, or gnomAD. The CADD phred score (https://cadd.gs.washington.edu/) and REVEL score was 24.8. and 0.695, respectively. The variant localizes to a highly conserved position, as demonstrated by PhyloP (5.327), PhastCons (1) score, and multispecies sequence alignment (Figure 1C). Figure 1 with 1 supplement see all Download asset Open asset Genotype of patients with variants in CRMP1. (A) Pedigree of index families. (B) Pictogram representing the CRMP1 cDNA with identified variant of proband 1 (P1) in exon 12 (c.1766C>T, NM_001014809.2) which leads on protein level to an amino acid change of proline to leucine in CRMP1 (CRMP1A-long form (p.P589L, NP_001014809.1) and CRMP1B-short form (p.P475L, NP_001304.1)); the variant in proband 2 (P2) in exon 9 c.280C>T (NM_001014809.2) leads to an exchange of threonine to methionine (CRMP1A (p.T427M, NP_001014809.1) and CRMP1B (p.T313M, NP_001304.1)); the variant in proband 3 (P3) in exon 6 c.052T>C (NM_001014809.2) leads to an exchange of phenylalanine to serine (CRMP1A (p.(F351S), NP_001014809.1) and CRMP1B (p.(F237S), NP_001304.1)). (C) Multispecies sequence alignment localizes the variants in the highly conserved area of CRMP1. (D) The short form CRMP1 monomer is composed of three structural parts, an N-terminally located seven β-strands forming two β-sheets (depicted in blue), followed by a linker β-strand (yellow) connecting to the central α/β-barrel (cyan/magenta) formed by seven repeats. Inserted after repeat 4 are 2 additional α-helices (gray). (E) CRMP1 assembles into tetramers. The relevant sites of T313M, P475L, and F237S are indicated as sphere model, with the T313 and F237 located in the central channel in the vicinity of the interaction sites and P475 is located at the beginning of the C-terminal helix and oriented toward the adjacent molecules. (F) The variant P475L reveals serious clashes with neighboring residues (red hexagonals) which may be accounted for by a shift of the helix as shown in (G). (H) Detailed representation of the structural vicinity of the T313M (yellow) to the ligand-binding cavity (magenta). (I) Magnified view of interface 1 tilted 90° backwards with respect to panel E highlighting the arrangement of the two phenylalanines at position 237 from the neighboring units. The exchange of phenylalanine with hydrophobic residues to serine with hydrophilic side chain interferes with the stability of the interaction in interface 1. Table 1 Phenotype of patients with CRMP1 variants. Characteristics and symptomsProband 1 (pedigree 1)Proband 2 (pedigree I1)Proband 3 (pedigree I1I)CRMP1 variant(NM_001014809.2);(NP_001014809.1)c.1766C>T;p.P589Lc.1280C>T;p.T427Mc.1052T>C;p.(F351S)ParentsNon-consanguineousNon-consanguineousNon-consanguineousGenderFemaleMaleFemaleAge at last assessment (years)151013Anthropometric dataNormalNormalOvergrowth Weight (kg)57.1 (0.15 SD)N/A133 (14.2 SD) Height (cm)168 (0.43 SD)166.5 (2.94 SD) OFC (cm)53.5 (−1.02 SD)62 (5 SD)Pregnancy, birth, postnatal adaptionNormalNormalNormal singular umbilical artery+−− macrosomia−+− fetal fingerpads−+−Microcephaly (OFC <−2 SD)−−−Macrocephaly (OFC >−2 SD)−−+ (5 SD)Facial dysmorphism−−+Delayed motor development+++ walking unsupported28 months24 months24 monthsGlobal muscular hypotoniaMildMildMildDeep tendon reflexesNormalNormalNormalIntellectual disabilityModerate (IQ 55)No (IQ 95)ModerateAutism spectrum disorder−+−Behavioral problems+++ lack of distance, sexualized behavior+−− hyperphagia−++Delayed speech and language development(first words spoken)+(24 months)+(36 months)+(30 months)Fine motor problems+−+Other secondary enuresisNocturna−++ pes planus−+− obesity−++EEG resultsNormalNormalNormalCranial MRI abnormalities−−− +, yes; −, no; IQ, intellectual quotient; N/A, not available; OFC, occipitofrontal circumference; SD, standard deviation. Proband 2 (P2) was born as the second child of non-consanguineous parents of Caucasian descent after an uneventful pregnancy and delivery (Figure 1A, Table 1). Routine echographia during pregnancy did not show of any concern. The boy was macrosomic at birth but had no congenital microcephaly. His motor development was delayed (unsupported walking at 24 months-of-age) due to congenital mild muscular hypotonia with normal deep tendon reflexes, but no coordination problems. He had bilateral pes planus. A speech delay and language impairment with first words spoken at 36 months were diagnosed. He was also diagnosed with an ASD and normal cognitive abilities (IQ 95). At last assessment at 10 years-of-age, an obesity associated with hyperphagia was of raising concern, and he had secondary enuresis nocturna. The body mass index (BMI) at last evaluation was 26.1. The results of a cranial MRI and EEG were normal. Routine metabolic screening showed no abnormal results. Similarly, through WES followed by bioinformatic analysis, we identified a heterozygous de novo variant c.1280C>T in the CRMP1 gene (NM_001014809.2; Chr4 (GRCh37):g.5841279G>A) in proband (P2) (Figure 1B). This variant leads to an exchange of threonine to methionine at position 427 in the long form, CRMP1A (p.T427M, NP_001014809.1) and at position 313 in the short form, CRMP1B (p.T313M, NP_001304.1) (Figure 1B). The variant affects a highly conserved region of the protein (Figure 1C). The CADD phred score and REVEL score were 27.7 and 0.819, respectively. PhyloP (5.093), PhastCons (1) score, and multispecies sequence alignment show that the variant is in a highly conserved region (Figure 1C). Proband 3 (P3) is the first child of three of a non-consanguineous family of European descent (Figure 1A, Table 1). She was born at gestation week 40 after an uneventful pregnancy, with normal birth parameters (weight: 3.610 kg, height: 50 cm, head circumference: 32.5 cm, Apgar score: 10/10). She had developmental delay with not being able to sit alone at 11 months and walked without support at 24 months. Her speech development was delayed with few words spoken at 30 months. She began to gain weight from 18 months, and overgrowth was noticed since the age of 2 years. At the age of 6 years, cell blood count, ionogram, lipid profile, endocrinological screening, and leptin blood level were normal with low-density lipoprotein (LDL) cholesterol: 3.16 mmol/l (2.60–4.00), total cholesterol/high-density lipoprotein (HDL) cholesterol ratio: 3.9 mmol/l (<4.4), serum triglycerides: 0.47 mmol/l (0.42–1.40), HbA1C: 5.4% (4.0–6.0), thyroid stimulating hormone (TSH): 3.27 µUI/ml (0.15–3.70), FT4: 10.25 ng/l (6.10–11.20), Cortisolemia: 92 µg/l (7.87–14.45), and Leptinemia: 131 ng/ml (19–251). There is familial history of obesity on both parental sides, and the father is macrocephalic (head circumference: 60.5 cm). She developed severe behavioral issues with temper tantrums, stubbornness, hyperphagia, obsessive–compulsive characteristics and ASD. She was attending special educational school at the age of 8. At the last assessment of 13 years-of-age, she had moderate intellectual disability and persistent severe behavioral disorders. Distinctive facial features were low forehead hair insertion, anteverted and large earlobes, broad nasal tip, short philtrum, and full lower lips. Genu valgum and hyperlordosis as well as abdominal and dorsal stretch marks were noted. Enuresis was noted. Cerebral MRI and abdomino-renal ultrasound were normal. Metabolic disorder screening and storage disease screening were negative, serum insulinemia was elevated: 32 mUI/ml (<25) with normal glycemia (0.9 g/l). Array analysis revealed two maternally inherited deletions: a 668 kb deletion at 3q26.31 and a 371 kb at 5q23.1, confirmed by genome sequencing and considered as variant of unknown significance. Further analysis through trio-based whole-genome sequencing identified a de novo variant in the CRMP1 gene c.1052T>C (NM_001014809.2; Chr4 (GRCh37):g.5841409A>G) (Figure 1B) and the mutation was confirmed by Sanger sequencing (Figure 1—figure supplement 1). The identified variant leads to an exchange of phenylalanine to serine at position 351 of long form of CRMP1 (CRMP1A (p.(F351S), NP_001014809.1)) and at position 237 in short form (CRMP1B (p.(F237S), NP_001304.1)) and it is located in the highly conserved region of the protein (Figure 1C). This variant is not found in gnomAD database. In silico pathogenicity prediction tools predict the identified variants to be deleterious (CADD phred: 23.60; REVEL 0.577), and the variant is located in the highly conserved region (PhyloP (2.826), PhastCons (1)). No additional pathogenic variants have been identified by trio genome sequencing, including all known genes involved in neurodevelopmental disorder. Effect of identified CRMP1 variants on protein structure Since CRMP1 is known to oligomerize to form homotetramers and heterotetramers along with other CRMPs to regulate cellular functions (Wang and Strittmatter, 1997), we determined the effect of the identified human variants on its protein structure using known structures and protein structure prediction tools. The structure of CRMP1 short form, CRMP1B, has been determined at 3.05 A resolution (Liu et al., 2015) lacking the N-terminal 14 residues and residues 491–572 in their C-terminal region. A CRMP1 monomer consists of three structural parts, N-terminal β-strands followed by a linker β-strand connected to the central α/β-barrel (Figure 1D). Several residues contribute to the oligomerization interface of CRMP1 and the quaternary structure of CRMP1 tetramer is shown in Figure 1E. The amino acids (P475, T313, and F237) are located in the highly conserved region of CRMP1. The P475 is the last residue before the start of the C-terminal helix and the exchange of proline to leucine (p.(P475L)) is predicted to lead to serious clashes with the neighboring residues (Figure 1F). Such spatial constraints may alter the dipole moment of the helix and lead to long-range allosteric effects (Figure 1G). The T313 lies within the region of the α/β-barrel and oriented toward the inside of the protein and located close to one of the two cavities (highlighted in yellow) (Figure 1H). These two cavities are located in between two pockets (highlighted in magenta). Conformational changes within these pockets upon function or interaction with other molecules could shuffle these cavities to form a channel required for function. The exchange of threonine to methionine (p.(T313M)) is predicted to prevent the conformational changes which might affect the interaction of CRMP1 with other molecules and/or oligomerization. The F237 is localized directly in the center of interface 1 so the exchange of a heavy hydrophobic sidechain by a hydrophilic short sidechain (p.(F237S)) most likely interferes with the stability of the dimer interaction (Figure 1I). Based on structural simulations, all three variants are predicted to affect the ternary structure of CRMP1 and impact on its oligomerization. P475L and T313M variants affect homo-oligomerization of CRMP1B To analyze the effect of CRMP1 variants on its protein levels and cellular function, two variants (CRMP1B-P475L (P1) or -T313M (P2)) were chosen for further functional analysis. The alternate splicing of exons 1a and 1b of CRMP1 gene brings two splicing variants CRMP1A (686 aa, long form) and CRMP1B (572 aa short form) (Figure 1B). CRMP1B is the major isoform expressed in the nervous system and most of CRMP1 studies including X-ray structural analysis have been performed with CRMP1B and therefore we used CRMP1B isoform for the experiments. We purified the recombinant human CRMP1B-wildtype, -P475L (P1), or -T313M (P2) proteins using the E. coli GST-tag expression system. CRMP1B-wildtype showed two major 64 and 60 kDa bands on SDS-denatured gel electrophoresis (Figure 2A, left lane). The 64 and 60 kDa correspond to full-length CRMP1B and to a truncated, C-terminal region cleaved form, respectively. The yield of purified T313M (TM) or P475L (PL) was less than that of wildtype in the same condition (Figure 2A, middle and right lanes). This finding may be due to lower expression and/or aggregation of the variant proteins in E. coli. As T313M and P475L mutated residues are positioned close to the dimer/tetramer interface of CRMP1B, these variants may affect homo-oligomerization of CRMP1. We therefore examined the oligomerization of recombinant CRMP1 preparation with gel-filtration chromatography (Figure 2B). Truncated CRMP1B-wildtype (lower band) was present in the high molecular weight region (200–500 kDa) and full-length CRMP1B (higher band) was present between 400 and 100 kDa. The high molecular weight signal probably represents the homo-oligomerization of CRMP1B-wildtype under the native condition. In contrast, CRMP1B-T313M and -P475L were detected at the lower molecular weight region (40–200 kDa). The molecular size (120 kDa) of peak fractions of T313M and P475L may indicate the dimerization of these variant proteins. Figure 2 Download asset Open asset Attenuated oligomer formation of CRMP1B-P475L and CRMP1B-T313M variants. (A) Purified CRMP1B-wildtype, -T313M, and -P475L recombinant proteins on sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) stained with CBB. GST-tagged CRMP1 were expressed in E. coli and purified through the binding to glutathione resin and the digestion with PreScission protease. Equal volume (2.5 µl) of the purified specimens, which were prepared under the same condition, were loaded on the gel. The yield of the variants was less than that of CRMP1-wildtype as shown in panel. Two major 64 and 60 kDa bands in the preparations are full-length and a truncated form, respectively. (B) Fractionation of CRMP1B specimens by size-exclusion chromatography. Purified CRMP1B specimens (150 µg) were passed through a Sephacryl S-300 column and the resultant flows/elution volumes were fractionated at every 1 ml. SDS–PAGE for 43–77th fractions were carried out after 20 times concentration. The distribution of molecular weights of standard proteins (44–660 kDa) at the same condition was displayed on the top of the gels. (C) Reduced homophylic interaction of CRMP1B variants. HEK293T cells coexpressing Myc-tagged CRMP1B-wildtype and either one of V5-tagged CRMP1B-wildtype, -T313M, or -P475L were analyzed by co-immunoprecipitation with anti-Myc-antibody. Immunoprecipitated specimens and input lysates were subjected to anti-V5 and anti-Myc immunoblot analyses. Co-immunoprecipitation of V5-tagged CRMP1 variants were reduced comparing to of wildtype CRMP1-V5. (D) Quantification of the V5-signal of Myc-immunoprecipitated specimens and of input lysate. The V5-signal ratios of CRMP1B-T313M and CRMP1B-P475L were significantly decreased compared to the ratio of CRMP1B-wildtype. The graph represents V5-signal ratio of each condition from six independent experiments (n=6). Data were analyzed by one-way repeated measures analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. **p < 0.01. Abbreviations: CRMP1B-wildtype, wt; CRMP1B-T313M, TM; CRMP1B-P475L, PL. Figure 2—source data 1 CRMP1 variants impact the homo-oligomerization. https://cdn.elifesciences.org/articles/80793/elife-80793-fig2-data1-v3.zip Download elife-80793-fig2-data1-v3.zip Figure 2—source data 2 Ratio of signal intensity of myc-IP band and input ratio of V5 blot. https://cdn.elifesciences.org/articles/80793/elife-80793-fig2-data2-v3.zip Download elife-80793-fig2-data2-v3.zip We further examined the homophilic interaction of CRMP1B-wildtype and the variants. HEK293T cells were co-transfected with Myc-tagged CRMP1B-wildtype together with either one of V5-tagged CRMP1B-wildtype, CRMP1B-T313M, or CRMP1B-P475L. The cells were subjected to anti-Myc-immunoprecipitation. As shown in Figure 2C, while V5-tagged CRMP1B-wildtype was strongly co-immunoprecipitated with Myc-tagged CRMP1B-wildtype, co-immunoprecipitation of V5-tagged CRMP1B-T313M or -P475L was reduced. Immunoprecipitated and input V5-signal ratios from CRMP1B-T313M and CRMP1B-P475L were significantly decreased compared to CRMP1B-wildtype (Figure 2D). These results suggest that the amino acid exchange in the CRMP1 variants may interfere with the homophilic interaction of CRMP1 and homo-oligomerization. P475L and T313M variants attenuate neurite outgrowth of cortical neurons We next asked whether the ectopic expression of CRMP1B variants in primary cultured murine cortical neurons affect the neuronal development. Dissociated E15 mouse cortical neurons were electroporated with the expression vector harboring either V5-CRMP1B-wildtype (wt), -T313M (TM), -P475L (PL), or tdTomato. The cells were seeded onto PLL-coated culture dishes and grown for 6–7 days. After fixation, the cells were immunostained with anti-V5 and anti-MAP2 antibodies. We found that the longest primary neurites of V5-CRMP1B-T313M or -P475L transfected neurons were shorter than those of V5-CRMP1B-wildtype (wt) or tdTomato transfected cells (Figure 3A–D). We then measured the length of the longest primary neurite from V5- or tdTomato-positive neurons in each condition. The longest primary neurites expressing CRMP1B-T313M or -P475L were 40–50% shorter than those expressing CRMP1B-wildtype (wt) (Figure 3E). As the longest primary neurites of the cultured cortical neurons are thought to be axons, these CRMP1B variants may interfere with the oligomerization of CRMP1 in turn to attenuate the outgrowth of the cortical axons. Figure 3 Download asset Open asset Attenuated neurite outgrowth by the ectopic expression of CRMP1B- P475L and CRMP1B-T313M variants. Representative images of the neurons expressing V5-CRMP1B-wildtype (A), -T313M (B), -P475L (C), or tdTomato (D). Transfected neurons were visualized by anti-V5 immunostaining or tdTomato expression (red) and anti-MAP2 immunostaining (green). The longest primary neurites of the neurons expressing V5-CRMP1B-T313M or -P475L were shorter than those of the neurons transfected with V5-CRMP1B-wildtype or tdTomato. Scale bars, 100 μm. (E) Longest primary neurite length. The length of the longest primary neurite from V5- or tdTomato-positive neurons was scored in each condition. The graph represents average ± standard error of the mean (SEM) with individual values from four independent experiments. The number (n) of examined neurons in each condition: CRMP1B-wildtype, 66; -T313M, 64; -P475L, 49; tdTomato, 73. Data were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. ***p < 0.001. Figure 3—source data 1 Quantification of longest neurite length. https://cdn.elifesciences.org/articles/80793/elife-80793-fig3-data1-v3.zip Download elife-80793-fig3-data1-v3.zip Discussion In this study, we report the human phenotype associated with heterozygous CRMP1 variants in three affected children of unrelated non-consanguineous pedigrees. All the patients have a neurodevelopmental disorder with motor delay and muscular hypotonia. While patient P1 has moderate intellectual disability and behavioral abnormalities, P2 was diagnosed with an ASD but a normal cognitive profile, and P3 presented with moderate intellectual disability and ASD. We showed that those human CRMP1 variants impact the oligomerization of CRMP1 proteins. CRMP1 exists as homo- or hetero-tetramers to interact with various signaling molecules and to link microtubules to subcellular structures and regulate cytoskeletal dynamics (Wang and Strittmatter, 1997; Nakamura et al., 2014). In line with this, CRMP1 colocalizes to the mitotic spindles and centrosomes, indicating of playing a key role in regulating mitosis and cell cycle progression (Shih et al., 2003). Defective cell cycle, abnormal mitotic spindle and centrosomes are the common key pathomechanisms underlying several neurodevelopmental disorders (Zaqout and Kaindl, 2021). Dysregulation of other CRMPs that have been linked to human disease has been shown to affect specific cellular processes associated with the clinical phenotype. For example, missense variants of CRMP5 impede the ternary complex formation with microtubule-associated protein 2 (MAP2) and beta-III-tubulin, thereby causing a defective inhibitory regulation on neurite outgrowth and dendritic development and thereby contribute to the brain malformation phenotype (Jeanne et al., 2021). MAP2 has been already reported to play a key role in neurite outgrowth and synaptic plasticity through its role in microtubule stabilization and cytoskeletal association (Kaech et al., 2001; Sánchez et al., 2000). Also, variant CRMP4 was shown to affect axonal growth and survival of motor neurons and thereby contribute to the amyotrophic lateral sclerosis phenotype (Blasco et al., 2013). In this study, we showed that the identified CRMP1 variants affect neurite outgrowth, which is a characteristic phenotype associated with many neurodevelopmental/psychiatric disorders (Prem et al., 2020). Our finding is in line with the reduced neurite outgrowth phenotype and impaired long-term potentiation in the Crmp1−/− mice (Su et al., 2007). Mechanistically, these cellular processes are regulated in a spatiotemporal manner through CRMP1 phosphorylation by several kinases such as Cdk5, Rho/ROCK, or GSK3, and any disturbances in these kinases or mutation of specific residues culminates in the abnormal brain development (Yamashita et al., 2006; Su et al., 2007; Charrier et al., 2006; Makihara et al., 2016; Uchida et al., 2005; Yamashita and Goshima, 2012). In the case of Cdk5−/− mice, abnormal dendritic spine morphology was shown in cortical neurons as it was in Crmp1−/− mice. Intriguingly, both mouse models show schizophrenia-like behavior, indicating the commonly shared cellular mechanism for dendritic development (Su et al., 2007; Yamashita et al., 2013) In the hippocampal slices of both Crmp1+/− and Crmp1−/− mice, LTP induction was impaired (Su et al., 2007). This highlights the importance of normal expression of Crmp1 for learning and memory in mice. In the context of neuronal development, defective phosphorylation of tyrosine residues in CRMP1 by Fyn-mediated Reelin signaling impairs cortical neuron migration (Yamashita et al., 2006). Over the last two decades, new phosphorylation-specific sites in CRMP1 are being reported and recently, phosphorylation of Tyr504 residue by Fyn has been shown to play an important step in Sema3A-regulated dendritic development of cortical neurons (Kawashima et al., 2021) Recently, phosphorylation of Crmp1 at Ser522 has been reported to play role in the ALS pathogenesis (Asano et al., 2022; Kawamoto et al., 2022). In this study, we showed that the reported CRMP1 variants lead to lost-of-function and overexpression of wildtype CRMP1 might be considered as a potential therapeutic strategy to rescue the phenotype. In conclusion, we report for the first-time human CRMP1 variants, link them to a human neurodevelopmental disease and highlight underlying pathomechanisms. Our report adds CRMP1 to list of other CRMP genes linked to neurological disorders and underlines the important role of CRMP1 in the nervous system development and function. As a future perspective, it will be interesting to find other CRMP1 variants and elucidat" @default.
• W4313305164 created "2023-01-06" @default.
• W4313305164 creator A5022620276 @default.
• W4313305164 creator A5031315906 @default.
• W4313305164 creator A5045211979 @default.
• W4313305164 creator A5046973045 @default.
• W4313305164 creator A5048426520 @default.
• W4313305164 creator A5054877182 @default.
• W4313305164 creator A5057248304 @default.
• W4313305164 creator A5065838297 @default.
• W4313305164 creator A5066208043 @default.
• W4313305164 creator A5066913919 @default.
• W4313305164 creator A5067376695 @default.
• W4313305164 creator A5071730923 @default.
• W4313305164 creator A5074016785 @default.
• W4313305164 creator A5075919574 @default.
• W4313305164 creator A5086609141 @default.
• W4313305164 creator A5091047296 @default.
• W4313305164 date "2022-12-09" @default.
• W4313305164 modified "2023-10-15" @default.
• W4313305164 title "Author response: Monoallelic CRMP1 gene variants cause neurodevelopmental disorder" @default.
• W4313305164 doi "https://doi.org/10.7554/elife.80793.sa2" @default.
• W4313305164 hasPublicationYear "2022" @default.
• W4313305164 type Work @default.
• W4313305164 citedByCount "0" @default.
• W4313305164 crossrefType "peer-review" @default.
• W4313305164 hasAuthorship W4313305164A5022620276 @default.
• W4313305164 hasAuthorship W4313305164A5031315906 @default.
• W4313305164 hasAuthorship W4313305164A5045211979 @default.
• W4313305164 hasAuthorship W4313305164A5046973045 @default.
• W4313305164 hasAuthorship W4313305164A5048426520 @default.
• W4313305164 hasAuthorship W4313305164A5054877182 @default.
• W4313305164 hasAuthorship W4313305164A5057248304 @default.
• W4313305164 hasAuthorship W4313305164A5065838297 @default.
• W4313305164 hasAuthorship W4313305164A5066208043 @default.
• W4313305164 hasAuthorship W4313305164A5066913919 @default.
• W4313305164 hasAuthorship W4313305164A5067376695 @default.
• W4313305164 hasAuthorship W4313305164A5071730923 @default.
• W4313305164 hasAuthorship W4313305164A5074016785 @default.
• W4313305164 hasAuthorship W4313305164A5075919574 @default.
• W4313305164 hasAuthorship W4313305164A5086609141 @default.
• W4313305164 hasAuthorship W4313305164A5091047296 @default.
• W4313305164 hasBestOaLocation W43133051641 @default.
• W4313305164 hasConcept C104317684 @default.
• W4313305164 hasConcept C54355233 @default.
• W4313305164 hasConcept C86803240 @default.
• W4313305164 hasConceptScore W4313305164C104317684 @default.
• W4313305164 hasConceptScore W4313305164C54355233 @default.
• W4313305164 hasConceptScore W4313305164C86803240 @default.
• W4313305164 hasLocation W43133051641 @default.
• W4313305164 hasOpenAccess W4313305164 @default.
• W4313305164 hasPrimaryLocation W43133051641 @default.
• W4313305164 hasRelatedWork W1991523530 @default.
• W4313305164 hasRelatedWork W2002128513 @default.
• W4313305164 hasRelatedWork W2009966535 @default.
• W4313305164 hasRelatedWork W2020824267 @default.
• W4313305164 hasRelatedWork W2031436818 @default.
• W4313305164 hasRelatedWork W2057739827 @default.
• W4313305164 hasRelatedWork W2075354549 @default.
• W4313305164 hasRelatedWork W2088063203 @default.
• W4313305164 hasRelatedWork W2171277769 @default.
• W4313305164 hasRelatedWork W2092874662 @default.
• W4313305164 isParatext "false" @default.
• W4313305164 isRetracted "false" @default.
• W4313305164 workType "peer-review" @default.